search
Back to results

Aspirin Responsiveness in Women at Risk for Cardiac Events

Primary Purpose

Heart Disease

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Aspirin
Sponsored by
Creighton University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Heart Disease

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women at least 19 years old
  • Taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease.
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Known CHD
  • Currently taking clopidogrel or ticlopidine
  • Use of heparin, warfarin, or glycoprotein IIb/IIIa inhibitors within previous 96 hours
  • Allergy or hypersensitivity to salicylates
  • Use of other OTC or prescription analgesics or anti-inflammatory medication in the past two weeks
  • Currently participating in another investigational drug or device study

Sites / Locations

  • The Cardiac Center at Creighton University

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

Aspirin 81mg

Arm Description

Resistant

Outcomes

Primary Outcome Measures

Number of Women Aspirin Resistant
Aspirin responsive unit (ARU) > 550 was considered to be aspirin resistant and correlates to less than 50% inhibition of platelet aggregation.

Secondary Outcome Measures

Number of Aspirin Resistant Who Became Responders After Increase to Aspirin 325 mg
Aspirin resistance was defined as ARU > 550

Full Information

First Posted
January 6, 2009
Last Updated
November 6, 2012
Sponsor
Creighton University
search

1. Study Identification

Unique Protocol Identification Number
NCT00818337
Brief Title
Aspirin Responsiveness in Women at Risk for Cardiac Events
Official Title
Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
June 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Creighton University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aspirin 81mg
Arm Type
Active Comparator
Arm Description
Resistant
Intervention Type
Drug
Intervention Name(s)
Aspirin
Intervention Description
Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
Primary Outcome Measure Information:
Title
Number of Women Aspirin Resistant
Description
Aspirin responsive unit (ARU) > 550 was considered to be aspirin resistant and correlates to less than 50% inhibition of platelet aggregation.
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
Number of Aspirin Resistant Who Became Responders After Increase to Aspirin 325 mg
Description
Aspirin resistance was defined as ARU > 550
Time Frame
2 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women at least 19 years old Taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease. Able and willing to provide informed consent Exclusion Criteria: Pregnancy or breastfeeding Known CHD Currently taking clopidogrel or ticlopidine Use of heparin, warfarin, or glycoprotein IIb/IIIa inhibitors within previous 96 hours Allergy or hypersensitivity to salicylates Use of other OTC or prescription analgesics or anti-inflammatory medication in the past two weeks Currently participating in another investigational drug or device study
Facility Information:
Facility Name
The Cardiac Center at Creighton University
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68131
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Aspirin Responsiveness in Women at Risk for Cardiac Events

We'll reach out to this number within 24 hrs